Sponsored by: STEMCELL Technologies
Session ends: May 30th, 2013, 3:00pm MST
Answers by: Dr. Vivian Lee, Senior Scientist , at STEMCELL Technologies
Induced pluripotent stem (iPS) cell-based models hold tremendous potential for the study of human neurological disease. Advances in technologies, including improvements in the ease and efficiency of generating neural progenitor cells from iPS cells, have resulted in increased adoption of these models by the neuroscience community. STEMCELL Technologies recently hosted a webinar in which the applications, features and workflow for this research model were presented
, together with an example of how Dr. Marina Bershteyn (UCSF) uses iPS cell-derived neural cells to model lissencephaly.
There are many options available to researchers interested in developing iPS-based models to complement traditional methods of neuroscience research. Points of consideration include the type of somatic cell used to generate the iPS colonies, the reprogramming system, the conditions under which iPS cells are maintained, the protocols used for neural induction and terminal differentiation, and the end-point assays used to investigate disease phenotype.
Use of defined and optimized reagents for the entire workflow facilitates the establishment of a robust model and increase experimental reproducibility. STEMCELL Technologies offers tools to support each step of the process, from TeSR™-E7™ reprogramming medium through to mTeSR™1 maintenance medium and STEMdiff™ differentiation reagents.
This session is sponsored by STEMCELL Technologies
Dr. Vivian Lee, Senior Scientists at STEMCELL Technologies, is happy to answer your questions regarding iPS-based modeling of neurological disease!
Questions & Answers
Currently, the most efficient non-integrating system is Sendai virus. For effective reprogramming, the reprogramming system and the reprogramming medium are both important variables. TeSR™-E7™(http://www.stemcell.com/en/Products/All-Products/TeSRE7.aspx) is an optimized xeno-free and defined reprogramming medium that enables the generation of high quality iPS cell colonies with reduced differentiation and fibroblast growth.» Read MoreIn theory, all somatic cells can be reprogrammed. Usually one would choose a cell source that is easier to obtain and expandable so that you can obtain a large number of starting cells. Fibroblasts fit both criteria and have been widely used. As a result, there are many papers and protocols available for reprogramming fibroblasts. […]» Read MoreIf you are referring to neural differentiation of human ES/iPS cells to generate neural progenitor cells (NPCs), the most common methods involve either embryoid body or monolayer culture systems. The same approaches have been used to generate progenitors from all three germ layers (ectoderm, mesoderm, endoderm), but specific growth factors or small molecules are normally […]» Read MoreThe EB protocol is slightly more labour intensive because there are more plating steps and neural rosette selection is required. However, the formation of morphologically distinct neural rosettes provides a quick and reliable readout of the success of neural induction, and rosette selection provides researchers with the ability to enrich for CNS-type neural progenitor cells. […]» Read MoreiPS cells derived from a patient’s somatic cells will retain the mutation or mutations that he/she carries. Thus, researchers can use this approach to study multifactorial/multigenetic diseases, including those with an unknown genetic identity eg. autism spectrum disorders.» Read MoreFor differentiation of ES and iPS cells to hepatocytes we recommend using the STEMdiff™ Definitive Endoderm Kit to generate definitive endoderm, in conjunction with Dr. David Hay’s protocol for downstream differentiation (Hay et al. Stem Cells, 2008). Cells differentiated using the STEMdiff™ Definitive Endoderm Kit express high levels of endoderm markers, including CD184 (CXCR4), SOX17, […]» Read More